The FDA has said new regulatory pathway is needed for CBD products so that regulatory oversight can manage food safety risks.
The US Food and Drug Administration has announced that, with there being a growing cannabidiol (CBD) market in the US, a new regulatory pathway is needed to manage risks.
What’s more the FDA has that it is prepared to work with Congress on this matter as well as announcing that it is denying three citizen petitions that asked the agency to conduct rulemaking to allow the marketing of CBD products as dietary supplements.
The Mayo Clinic has noted that CBD products, though often “well tolerated” following human consumption, can cause side effects, such as dry mouth, diarrhoea, reduced appetite, drowsiness.
In addition, the FDA has highlighted that the use of CDB raises various safety concerns, especially with long-term use. It says that studies have shown the potential harm to the liver, interactions with certain medications and possible harm to the male reproductive system.
What’s more, the FDA has said that CBD exposure is “concerning” when it comes to certain vulnerable populations such as children and those who are pregnant.
Explaining that a new regulatory pathway would “benefit consumers by providing safeguards and oversight to manage and minimize risks related to CBD products”, the FDA has noted that “some risk management tools could include clear labels, prevention of contaminants, CBD content limits, and…
